The British Association for Sexual Health and HIV (BASHH) have published new guidelines for the management of gonorrhoea infections with a strong focus on antimicrobial stewardship of last-line antibiotics. The guidelines call for antibiotic susceptibility testing and preferential use of ciprofloxacin, a previously used oral antibiotic, still effective for up to 70% of gonorrhoea infections. This move aims to limit the use of ceftriaxone, one of the last-line gonorrhoea treatments, to which a few strains have started to exhibit resistance.
The SpeeDx ResistancePlus® GC test is the first commercially available molecular test combining Neisseria gonorrhoeae (GC) detection with markers for ciprofloxacin susceptibility. ResistancePlus GC enables stewardship of last-line antibiotic treatments by directing therapy towards ciprofloxacin when appropriate and is directly in-line with the updated BASHH guidelines.
Read the full BASHH guidelines here.